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Summary: Urine samples (n = 300) were examined for drugs by thin-layer chromatography ("Drug Skreen", Brink-
mann Corp.) and by the "Enzyme Multiplied Immunoassay Technique" ("Emit", Syva Corp.). The results of both
methods were compared for the detection of opiates, barbiturates and amphetamines. In more than 90% of the
determinations identical results were obtained with both methods. About 10% of the results of the Emit barbiturate
assay differed from those of thin-layer chromatography and therefore had to be further investigated by gas liquid
chromatography. It could be demonstrated that the barbiturate determination by the Emit system correlated better
with the results of gas liquid chromatography. From the results of this study it is suggested that thin-layer chromato-
graphy is used as a screening test, and to confirm positive results with other methods such as Emit. If the abuse of
barbiturates or opiates is suspected the corresponding Emit test should also be performed, even in cases of a negative
thin-layer Chromatograph*, -screening. Confirmation with a third method such as gas liquid chromatography is
necessary, if thin-layer chromatography and Emit lead to divergent results.
Drogenscreening mit Enzymimmuntests (EMIT) und Dünnschichtchromatographie (Drug Skreen)
Zusammenfassung: Urinproben (n = 300) wurden dünnschichtchromatographisch („Drug Skreen", Brinkmann Corp.)
und mit Enzymimmuntests („Emit", Syva Corp.) auf Drogen untersucht. Die Ergebnisse beider Methoden wurden für
den Nachweis von Opiaten, Barbituraten und Amphetaminen miteinander verglichen. In über 90% der Bestimmungen
fanden sich identische Resultate mit beiden Methoden. Etwa 10% der Ergebnisse des Emit Barbiturattests divergierten
mit denen der Dünnschichtchromatographie und mußten daher zusätzlich gaschromatographisch untersucht werden.
Es konnte gezeigt werden, daß die Barbituratbestimmung mit dem Emit System besser mit den Resultaten der Gas-
chromatographie korrelierte. Auf Grund der Ergebnisse dieser Studie wird vorgeschlagen, die Dünnschichtchromato-
graphie als Screenings-Test zu verwenden und positive Resultate mit anderen Methoden wie z. B. Emit zu bestätigen.
Bei Verdacht auf Barbiturat- und Opiatmißbrauch ist die zusätzliche Durchführung des entsprechenden Emit-Testes
auch in Fällen eines negativen Dünnschichtchromatographie-Screenings empfehlenswert. Die Bestätigung mit einem
dritten Verfahren wie z. B. Gaschromatographie ist erforderlich, wenn Dünnschichtchromatographie und Emit zu
divergenten Resultaten führen.
The treatment of dtug overdosage and the detection of The identification of drugs with thin-layer chromato-
drug abuse require rapid analytical methods for the graphic techniques alone is difficult. Therefore drugs
identification of drugs in biological material. have been eluted from the thin-layer plate and subse-
t , . quently examined by various methods such as color,In the past few years many thiiulayer Chromatographie H^ ^ ^
 hotometric tests (13)
techniques for the detection of drugs have been described ^ ^
 sensitive methods
(1-7). Instead of the time-consuming extraction of drugs
 for ^ verification of ^ .^  chromatographic
from unne with organic solvents Amberhte XAD-2
 ne geveral ^ ^
columns were proposed (8-12). Combinations of drug lca rr /
extraction by XAD-2 resin with a thin-layer ehromato-
graphic screening technique (3) are commercially avail- i) p^ of this study have been reported at Anaiytica 76 in
Munich 1976 (abstract: Z. Anal. Chem. 279, 132 (1976)).
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metliods such as radioimmunoassay, spin immuno-
assay, hemaglutination inhibition and enzyme immuno-
assay have also been applied for the detection of drugs
(14-23).
In the present study an enzyme immunoassay system
(Emit, Syva Corp.) was evaluated for its use in the
confirmation of opiates, barbiturates and amphetamines
detected by thin layer chromatography.
Materials and Methods
Origin of specimens
Urine samples (n = 300) were received from a drug abuse
rehabilitation center, from the State Health Department
Hannover, and from our hospital. Drug free control urine
was obtained from laboratory personal. Lyophilized human
urine spiked with various drugs (urine toxicology control pro-
ficiency and urine drug check kit) was purchased from Cyana-
mide GmbH (D-8000 Munich).
Materials
The reagents for the enzyme immunoassay (Emit) were purchased
from Syva Corp., Palo Alto, Calif, and materials for thin-layer
chromatography (Drug Skreen) from Macherey & Nagel
(D-5160 Diiren). Materials for gas liquid chromatography were
obtained from Supelco (Bellfonte, Pa, USA) and all other -
chemicals from Merck AG (D-6100 Darmstadt).
Thin-layer chromatography (Drug Skreen)
Thin-layer Chromatographie determinations were performed
according to the manufacturer's instructions. The drugs were
extracted by disposable Amberlite XAD-2 columns and separated
by thin-layer chromatography on silica gel coated glass plates
(solvent system: ethyl acetate/methanol/330 g/1 ammonium
hydroxide, 17 ml + 2 ml + 1 ml). For visualization of the drugs
UV radiation, heat and group specific reagents were applied to
the plates. With each plate a control urine was processed con-
taining morphine, codeine, meperidine, methadone, ampheta-
mine, pheno-, seco- and amorbarbital at levels of 1-3 mg/L The
Rf-values of drugs were calculated relative to amobarbital (1).
Drugs were identified by their relative Rf-value, color reaction
and the comparison with the reference substances on the same
plate. Detection criteria of various drugs are given in table 1
and 2. Blind controls were performed with toxicological control
urine (urine drug check kit, Lederie Diagnostics).
Enzyme immunoassay (Emit)
The original procedure of the enzyme immunoassay for the
detection of drugs in urine (18) was slightly modified to in-
corporate the Eppendorf system 5085 (tab. 3). The further
evaluation of the results was performed according to the
manufacturer's instructions. At the beginning and end of
each series a urine sample spiked with the drug tested was
analyzed as precision control. The quantitative determination
of phenobarbital in serum by Emit was performed with an
Eppendorf analyzer 5010 (tab. 4).
Gas-liquid chromatography
After the addition of 5 jug hexobarbital as internal standard the
urinary samples were purified by chromatography on Amberlite
XAD-2. The eluates were evaporated under vacuum. The residues
were dissolved in a small volume of ethyl acetate/acetic acid
(100 ml + 1 ml) and applied to an aluminium sheet coated with
silica gel F2S4 (thickness of the layer 0.25 mm). The chromato-
gram was developed with ethyl acetate/methanol/330 g/1
ammonium hydroxide (17 m l + 2 ml+1 ml) and chloroform/
acetone (8 ml + 2 ml) at right angles to the first direction. The
zone containing the barbiturates was cut off and put into a glass
tube with a sealed-in sintered glass support (G 4) at the bottom.
Tab. 1. Detection criteria for hypnotics and sedatives.
Compounds (trade name)
Phenobarbital (Luminal)
Brallobarbital
Barbital (Veronal)
Cyclobarbital (Phanodorm)
Allobarbital (Dial)
Propylallylonal
Heptabarbital (Medomin)
Aprobarbital (Numal)
Vinylbital
Methylphenobarbital (Prominal)
Crotylbarbital
Butalbital (Sandoptal)
Cyclopal
Amobarbital (Amytal) .
Butabarbital
Pentobarbital (Neodorm)
Amylallylbarbital
Secobarbital (Seconal)
Thiogenal
Hexobarbital (Evipan)
Enibomal (Euriarcori)
Glutethimide (Doriden)
Methaqualone (Mandrax)b
Carbromal (Adalin)
Rf valuea
0.54
0.70
0.70
0.72
0.76
0.79
0.80
0.89
0.89
0.91
0.92
0.93
0.94
1.00
1.03
1.06
1,06
1.09
1.16
1.21
1.28
1.64
1,77
-
Color reaction
with dip hen yl-
carbazone/mer-
curie sulfate
violet
violet
violet
violet
white
violet
violet
white
violet
violet
violet
white
white
violet
violet
violet
violet
white
white
violet
violet
violet
NRC
NR
?) Relative to amobarbital. Solvent system: ethyl acetate/
methano 1/330 g/1 ammonium hydroxide, 17 ml + 2 ml + 1 ml.
k) Positive reaction with iodoplatinate and Dragendorffs reagent.
°) No reaction.
Tab. 2. Detection criteria for various drugs.
Compound (trade name) Rf Nin- iodo-
value3 hydrin platinate
Narcotics
Morphine
Codeine
Ketobemidone (Cliradon)
Levorphanol (Dromorari)
Pethidine (Dolantin)
Normethadone (Ticarda)
Levallorphan (Lorfan)
Methado'ne ( ,-Polamidon)
Methadone Metabolite
Stimulants
Methamphetamine (Pervitin)
Amphetamine (Benzedrin)
Strychnine
Fenethylline (Captagon)
Methylphenidate (Ritalin)
Bemegride (Eukraton)
Miscellaneous
Quinine0
4~Aminophenazone
Propylhexediine (Eventin)
Nicotine
Fenfluramine
Thioridazine (Melleril)
Diphenhydramine
Chlorpromazine (Megaphen)
Trifluopromazine (Psyquil)
Amitryptiline (Laroxyl)
0.41
0.72
1.09
1.19
1.28
1.28
1.59
1.64
1.70
0.68
0.96
0.68
1.32
1.43
.·=·
0.72
1.04
1.05
1.34
1.43
1.58
1.58
1.59
1.61
1.65
dark blue
brown
brown
brown-violet
violet
brown
brown^Violet
(pink) brown
(pink) brown
brown
pink
brown-violet
brown-violet
brown-violet
NRb
brown
pink (pink)
brown
green
brown
brown-yellow
brown
blue-violet
browri^violet
brown
a) Relative to amobarbital. Solvent system: ethyl acetate/
methanol/330 g/1 ammonium hydroxide, 17 ml + 2 ml + 1 ml.
k) No reaction.
°) fluorescence under uv-light.
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Tab. 3. Test procedure for the Emit drugs abuse urine assays
with the Eppendorf system 5085.
Tris-maleate buffer 0.025 mmol/1 pH 6.0
Bacterial suspension
Urine sample
750 μΐ
200 μΐ
50 μΐ
Preincubation: 10 min at 37 °C in polystyrene cuvettes (d = 1 cm)
Reagent A (antibody solution)
Reagent B (drug-enzyme conjugate)
50 μΐ
50 M!
Wavelength: 436 nm. First reading of absorbance 10 s and
second reading 34 s after addition of reagent B.
Tab. 4. Test procedure for the Emit phenobarbital assay with
Eppendorf analyzer 5010.
Serum
Reagent A (antibody/substrate/NAD)a
Preincubation: 15 min at 25 CC
Reagent B (drug-enzyme conjugate)3
10 M!
500 M!
100 M!
Wavelength: 334 nm, program GOT, temperature 25 °C. First
reading of absorbance 30 s and last reading 180 s after addition
of reagent B
a) Reagent A is diluted 1:13.5 and reagent B 1:2.5 with 55
mmol/1 Tris-HCl buffer (pH 7.9).
Elution was carried out with 5 ml chloroform/acetone (8 ml
+ 2 ml) and repeated once. The eluates were evaporated under
vacuum and after dissolution in ethyl acetate/acetic acid
(100 ml + 1 ml) analyzed by gas-liquid chromatography on the
following column packings: 3% SP-2250 DA Chromosorb
WHP 100-200 mesh, 3% Ov-101 on Chromosorb WHP
100-120 mesh, 3% CDMC on Chromosorb WHP 100-120 mesh.
A Varian gas Chromatograph series 2800 equipped with a double
flame ionisation detector and siliconized glass columns was
used. The barbiturates were identified by comparison of their
relative retention time (relative to hexobarbital) on various
columns and as control by the simultaneous injection of the
extract and the barbiturate supposed. The detection limit
dependends on the individual barbiturate and was at least
0.2 mg/1, if 20 ml urine were processed (K lpmann, W. R.t
unpublished).
Determination of detection limits
Commercially available control urine (urine toxicology
control drugs I, Lederle diagnostics) containing morphine
(3 mg/1), methadone (3 mg/1), amphetamine (5 mg/1) and seco-
barbital (5 mg/1) was diluted with drug free urine 1:3, 1:5 and
1:10. Then 20 ml of each dilution were extracted and processed
by thin layer chromatography. Concentrations at which spots
just could be detected visually on the thin-layer Chromato-
graphie plate are given as the detection limits of the various
compounds. With the various Emit assays the detection limits
were determined according to Kaiser (24) as the mean value
plus the 3 fold standard deviation of a series (n = 20) from drug
free, pooled urine.
Results and Discussion
Precision of the Emit system
The precision of the Emit assays for the detection of
drugs in urine was low (tab. 5). Therefore only a semi-
quantitative evaluation of the results appears suitable.
One reason for the low precision may be the turbidi-
metric technique. Typical Emit standard curves are
shown in figure 1. A better precision was found with
the Emit assays for methadone and opiate than with
those for amphetamine and barbiturate.
A considerable improvement of the precision and
accuracy was achieved with the recently developed Emit
assay for the quantitative determination of pheno-
barbital in serum (25-29). In this assay a NAD coupled
reaction was applied. Moreover this assay could be
mechanized with an Eppendorf analyzer 5010. The
coefficient of variation of the Emit phenobarbital
assay was 6.0% within series and 7.8% from day to day
(mean·value with standard deviation: 29.7 ±2.3 mg/1;
n = 40). Similar results have been observed, when this
Emit assay was performed on a Gilford spectrophoto-
meter (26, 28).
Tab. 5. The precision of the Emit system for the detection of
morphine (2.3 mg/1), methadone (2.7 mg/1), amphe-
tamine (2.2 mg/1) and secobarbital (2.8 mg/1) in spiked
human urine samples. Assays were performed in duplicate
on 20 days (n = 40).
Precision morphine methadone ampheta- secobarbital
mine
x(CV)* x(CV) x(CV) x(CV)
From 2.98(23.8) 1.95(34.4) 2.94(44.7) 1.67(39.1)
day-
to-day
Within 2.98(13.7) 1.95(13.3) 2.94(32.9) 1.67(31.4)
series
* mean value (x, mg/1) with coefficient of variation (CV, %).
0.080
0060
Q04
0,020
ι I j_ j_
0.2 0.3 0.5 10 2.0
Concentration [mg/l]
3.0 5.0 1QO
Fig. 1. Typical Emit standard curves for methadone ο—ο,
morphine ·—·, amphetamine ο—α and secobarbital
•—·. Vertical bars represent standard deviations
(n-3).
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In the following the sensitivity and specificity of
various Emit assays for the detection of drugs in urine
and the correlation of Emit with thin layer chromato-
graphy or gas liquid chromatography are described.
Results confirmed by thin layer chromatography (tab. 6)
or gas liquid chromatography (tab. 7, 8) were classified
as "true", divergent values as "false" positive or negative.
Barbiturates
Correlation of Emit and thin layer chromatography
with gas liquid chromatography
The results of the examination of 300 urine samples
for drugs of abuse by thin layer chromatography and
Emit were compared (tab. 6). About 10% of the barbi-
turate determinations yielded divergent results. There-
fore these cases were further investigated by gas liquid
chromatography. It could be demonstrated that the
results of the Emit barbiturate assay correlated in
Tab. 6. Comparison of the results obtained by the Emit system
and thin-layer chromatography for the detection of
various drugs in urine samples from about 300 patients.
Emit assays
Barbiturate Opiate Metadone Amphetamine
True 46 15.3 8 2.3 34 11.5 2 0.7
positive1*
True 223 74.4 332 94.8 254 86.1 292 95.1
negative15
Total 269 89.7 340 97.1 288 97.6 294 95.8
False
positive0
False
negative0
Total
10
21
31
3.3
7.0
10.3
8
2
10
2.3
0.6
2.9
6
1
7
2.1
0.3
2.4
1
12
13
0.3
3.9
4.2
a) n = number of samples.
") confirmed by thin-layer chromatography.
°) results divergent from thin-layer chiomatography.
Tab. 7. Gas-liquid Chromatographie confirmation of barbiturate
in urine samples (n = 31), for which divergent results
were obtained with thin-layer chromatography and the
Emit system.
Emit barbiturate Thin-layer
assay chromatography
True positiveb
True negative*5
Total
False positive0
False negative0
Total
5
15
20
3
8
11
16.1
48.4
64.5
9.7
25.8
35.5
8
3
11
15
5
20
25.8
'9.7
35.5
48.4
16.1
64.5
Tab. 8. Comparison of the results obtained by the Emit system,
thin*layer chromatography and gas-liquid Chromato-
graphie for the detection of barbiturate in urine samples
from 65 patients.
Emit barbiturate Thin-layer
assay chro matography
n,a n
True positive*5
True negative13
total
False positive0
False negative*?
Total
16
33
4?
6
10
16
24.6
50.8
75.4
9.2
15.4
24.6
19
20
39
19
7
26
29.2
30.8
60.0
29.2
10.8
40.0
*) n = number of samples.
k) confirmed by gas-liquid chromatography.
°) unconfirmed by gas-liquid chromatography.
*) n = number of samples.
") confirmed by gas-liquid chromatpgraphy.
°) results divergent from gas-liquid chromatography.
64.5 % and those of thin layer chromatography only in
35.5% with those of gas liquid chromatography (tab. 7).
A relatively high percentage of false negative results
occurred with thin layer chromatography and Emit,
as these methods were less sensitive than gas liquid
chromatography. False positive results were observed
with thin layer chromatography in 48.4% and with the
Emit system in 9.7% of the determinations, indicating
a rather low specificity of the thin layer chrorhato-
graphy.
When a larger collective of 65 patients chosen at random
was tested, 75 % of the results by the Emit system and
60% of those by thin layer chromatography could be
confirmed by gas liquid chromatography (tab. 8).
Again there were much more false positive results by
thin layer chromatography than by Emit The sensi-
tivity of Emit however appeared to be lower than that
of thin layer chromatography.
If thin layer chromatography was used in combination
with Emit the percentage of false positive results could
be reduced from 29 % to 5 % and that of false negative
ones from 11 % to 3%. Therefore it appears to be
suitable to confirm by Emit all of the positive results.
Thus a considerable reduction of wrong results can be
achieved very easily and only divergent results have
to be analyzed by time-consuming techniques such as
gas liquid chromatography. Samples negative by thin
layer chromatography should be determined in
addition by Emit, if barbiturate abuse is suspected, as
the combination of both methods yields less false
negative results.
So far urine samples from patients that suffered from
barbiturate poisoning had identical results by all of the
three methods mentioned above.
Specificity and sensitivity
Glutethimide was the only nonbarbiturate compound,
which cross^reacted in this Emit assay.
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Tab. 9. Cross-reactivity of drugs in urine3 with the Emit amphetamine and Emit barbiturate assay.
Emit amphetamine assay Emit barbiturate assay
Compound (trade name)
Amphetamine (Benzedrine)
Methamphetamine Hydro chloride (Pervitin)
Fenethylline Hydrochloride (Cap t agon)
Fenfluramine Hydrochloride (Ponderax)
Propylhexedrine Hydrochloride (Eventin)
Ephedrine Hydrochloride (Ephetonin)
D-Phenylethylamine
L-Phenylethylamine
Methylphenidate (Ritalin)
4-Aminophenazone
Phenylalaninc
Caffeine
Strychnine Nitrate
Norfenefrine Hydrochloride (Novadral)
Oxedrine Tartrate (Sympathol)
Isoprenaline Hydrochloride (Aiudrin)
Orciprenaline Sulphate (Alupent)
Bamethan Sulphate (Vasculat)
Etilefrine Hydrochloride (Effortil)
Vanilmandelic Acid
mg/lb Compound (trade name)
1.0 Secobarbital (Seconal)
0.7 Pentobarbital (Neodorm)
0.9 Hexobarbital (Evipan)
7.0 Methylphenobarbital (Prominal)
10.5 Cyclopal
13.5 Vinylbarbital
35.0 Phenobarbital (Luminal)
68.0 Amobarbital (Amytal)
NRC Cyclobarbital calcium (Phanodorm)
NR Amylallylbarbital calcium
NR Brallobarbital
NR Aprobarbital (Numal)
NR Heptabarbital (Medomin)
NR Butabarbital
NR Propallylonal
NR Butalbital (Sandoptal)
NR Crotylbarbital
NR Barbital (Veronal)
NR Allobarbital (Dial)
NR Thiogenal sodium
Thiopental (Trapanal)
Enibomal sodium (Eunarcon)
Glutethimide (Doriden)
Methyprylon (Noludar)
Carbromal (Adalin)
Bemegride (Eukraton)
mg/1
1.0
1.6
2.5
2.5
3.2
3.5
3.6
3.6
4.5
5.0
5.0
6.0
6.5
6.9
7.1
7.4
7.6
7.7
7.7
8.9
20.0
30.0
40.0
NR
NR
NR
a) drugs were added to normal human urine.
b) concentrations resulting in an absorbance equivalent to
1.0 mg/1 amphetamine or secobarbital.
°) no reaction up to concentrations of 500—1000 mg/L
Tab. 10. Detection limits of various drugs with the Emit system
and thin-layer chromatography.
Compound Emit Thin-layer
system chromato-
graphy3
Methadone (mg/1)
Morphine (mg/1)
Amphetamine (mg/1)
Secobarbital (mg/1)
0.2
0.3
0.4
0.5
1.0
0.6
1.0
1.0
a) these detection limits are based on the extraction of 20 ml
urine.
Most of the barbiturates were detectable by Emit at
concentrations between 1 and 10 mg/1 (tab. 9). The
detection limit of secobarbital was 0.5 mg/1 (tab. 10).
With all Emit assays tested the detection limits, how-
ever, were not used as "cutoff" values between nega-
tive and positive results. In agreement with the manu*
facturer higher "cut-off" points were chosen, in order
to decrease the risk of obtaining false positive results
due to endogenous lysozyme (18). We have found it
convenient to use the low calibrator reading (1.0 mg/1
of secobarbital) as cutoff with the Emit barbiturate
assay.
Tab. 11. Detection of drugs in urine samples of a urine drug
check kita (n = 23) by thin-layer chromatography
(TLC) and the Emit system. The urine samples con-
tained various combinations of barbiturates (1 mg/l),
opiates (1 mg/1), amphetamines (2 mg/1) and other
drugs.
Barbiturates Morphine Methadone Ampheta-
and deriva- mines
tives
TLC EMIT TLC EMIT TLC EMIT TLC EMIT
Results
Correct13
False
negativec
False
positived
20
1
2
18
4
1
19
2
2
22
0
1
20
0
3
23
0
0
23
0
0
23
0
0
*) Lederle diagnostics.
*0 Total number of correct results for the indicated drug.
Cf d) Total number of false negative and false positive results
respectively.
As the sensitivity of the barbiturate determination by
thin layer chromatography was about 1—5 mg/1, the
concentrations found iii urine after a therapeutic
barbiturate döse were detectable by both methods.
J. Clin, Chem.-Clin, Biochem. / VoL 15,1977 / No. 5 20*
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The results of blind controls (tab. 11) showed a rela-
tively high percentage of false negative results by Emit,
as the concentrations of some of the barbiturates such
as phenobarbital were already below the detection
limit.
Amphetamine
Sensitivity and Specificity
Although the detection limit of amphetamine was
lower with the Emit system than with thin layer chroma-
tography (tab. 10), the practical level of sensitivity was
about the same with both methods.
The specificity of the amphetamine assay appeared to
be rather low in view of the detection of a number of
interfering substances. Stimulants like methamphe-
tamine (Benzedrin), fenethylline (Captagon), ephedrine
(Ephetonin), propylhexedrine (Eventin) as well as
anoretics such as fenfluramine (Ponderax) cross-reacted
in this Emit assay at low concentrations (tab. 9).
Methylphenidate (Ritalin) showed no cross-reaction.
In addition to amphetamine, various stimulants were
detectable by thin layer chromatography. Unfortu-
nately 4-aminophenazone, a metabolite of dimethyl-
aminophenazone, behaved in our thin-layer Chromato-
graphie system like amphetamine (tab. 2). Therefore
repeatedly positive results were obtained with urine
samples from patients that had taken drugs such as
Optalidon which contain dimethylaminophenazone.
The presence of amphetamine could be excluded in
these cases by Emit.
Correlation of Emit with thin layer chromatography
With the Emit amphetamine assay only very few false
positive but a number of unconfirmed negative results
were observed (tab. 6). The latter were mostly due
to the interference of 4-aminophenazone with the
thin-layer Chromatographie amphetamine detection
and therefore correctly negative. The analysis of
blind control specimens yielded no false results (tab. 11).
However cross-reactions seem to occur, since, in contrast
to our study, Mule found 12.5% false positive results
with this Emit assay (19).
Morphine and derivatives
Sensitivity and specificity
The Emit system was more sensitive for the detection
of morphine than thin layer chromatography (tab. 10).
According to the manufacturer's recommendations the
"cut-off value above which samples are classified as
positive was chosen to be 0.5 mg/1. A further advantage
of the Emit system was the additional detection of mor-
phine glucuronide (18) and the small sample size of
50 . A comparable sensitivity was attained by thin
layer chromatography, providing 20 ml of urine were
extracted. Various narcotic drugs listed in table 2 were
detectable by thin layer chromatography at concentra-
tions of 0.6-5.0 mg/1.
The term Emit opiate assay seems to be incorrect,
as this test shows sufficient sensitivity only for few
opiates such as morphine, codeine and levorphanol
(tab. 12). Therefore the expression "Emit morphine
derivatives assay" would perhaps be more suitable.
The cross-reaction of codeine interferes with the detec-
tion of morphine abuse. Positive results are found very
often with urine samples from patients taking cough
drops, which contain codeine. Therefore the sole use of
the Emit opiate assay is only suited for the exclusion
of the opiates mentioned above.
Correlation of Emit with thin layer chromatography
Divergent results were obtained by Emit and thin layer
chromatography in only in 2.9% of the determinations
(tab. 6). The greater sensitivity of the immunoassay
appeared to be responsable for the majority of the
unconfirmed results. Similar data have been reported
by Mule (19). With the analysis of blind control speci-
mens more false results were obtained by thin layer
chromatography than by Emit (tab. 11).
Methadone
Sensitivity and specificity
Methadone was detectable by Emit at lower concentra-
tions than by thin layer chromatography (tab. 10).
With the Emit system values above 0.5 mg/1 were
classified as positive results.
The Emit methadone assay showed no absolute
specificity. Normethädone (tab. 12) and metabolites
of Z,<^acetyl methadol (30) were found to cross-react
in this assay.
The methadone detection by thin layer chromatography
appeared to be less specific. With blind control speci-
mens false positive results were observed by thin layer
chromatography but not by Emit (tab. 11).
Metabolites of methadone do not cross-react in the
Emit assay (19, 30). One metabolite of methadone was
detectable by thin layer chromatography (tab. 2).
The excretion of methadone and its metabolite depends
on the pH value of the urine: the ratio of methadone
metabolite/methadone is 1.0 at a pH of 4-5 and 40 at a
pH of 7.4-8.1 (31). Thus the detection of the metha-
done metabolite in alkaline urine by thin layer chromato-
graphy may be helpful in the detection of the use of
methadone.
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Tab. 12. Cross-reactivity of drugs in urinea with the Emit methadone and opiate assay.
Emit methadone assay
Compound (trade name)
Methadone
Normethadone (Ticarda)
Promethazine hydrochloride (Atosil)
Chlorpromazine hydrochloride (Megaphen)
Morphine hydrochloride
Codeine phosphate
Pethidine hydrochloride (Dolantin)
Levallorphan tartrate (Lorfan)
Levorphanol tartrate (Dromoran)
Ketobemidone (Cliradone)
Dextromoramide (Palfium)
Dextropropoxyphene
Triflupromazine hydrochloride (Psyquil)
Emit opiate assay
mg/lb Compound (trade name)
0.5 Morphine
4.0 Codeine phosphate
130.0 Levorphanol tartrate (Dromoran)
150.0 Ketobemidone (Cliradon)
190.0 Pethidine hydrochloride (Dolantin)
NRC Levallorphan tartrate (Lorfan)
MR Promethazine hydrochloride (Atosil)
NR Chlorpromazine hydrochloride (Megaphen)
NR Triflupromazine hydrochloride (Psyquil)
NR Methadone hydrochloride (/^Polamidon)
NR Normethadone (Ticarda)
N R Dextromoramide (Palfium)
NR
mg/1
0.5
0.4
2.5
50.0
70.0
100.0
260.0
310.0
NR
NR
NR
NR
a) drugs were added to normal human urine. **) concentrations resulting in an absorbance equivalent to 0.5 mg/1 methadone or
morphine. °) no reaction up to concentrations of 500—1000 mg/1.
Correlation of Emit with thin layer chromatography
The comparison of the results obtained by Emit and
thin layer chromatography in a series of about 300
patients showed a good correlation between both
methods. Only 2.4% of the results could not be con-
firmed by thin layer chromatography. The major
reason for this discrepancy seemed to be the greater
sensitivity of the Emit system. This finding is con-
sistent with observations of Mule (19).
Comparison of costs
The costs for reagents, pertinent supplies, standards
and technician time are listed in table 13. A detailed
calculation of the costs for technician time is reported
by L c. (32); meanwhile a presumable 36 percent in-
crease of labor costs was considered in our calculation.
If 30 samples were analyzed the price for a thin layer
chromatography-screening was about 6 DM and per
Emit test 4 DM. The costs for thin layer chromato-
graphy rise considerably, if commercially available toxi-
cological control urine is used. Single determinations
are very expensive with both methods.
Conclusion
From the results of our study the following procedure
for the detection of drugs is recommended (fig. 2):
At first a thin-layer Chromatographie screening test
is performed, which allows the detection of a large
variety of drugs.
Results positive for barbiturates, opiates or amphe-
tamines have to be confirmed by the corresponding
Emit assay. If divergent results are obtained, the further
investigation by a more specific method such as gas
liquid chromatography is necessary. In cases of suspected
abuse of barbiturates and opiates the additional per-
formance of the corresponding Emit assays is useful,
even if the thin layer chromatography screening is nega-
tive.
Further Emit assays for the determination of the meta-
bolites of cocaine and benzodiazepine are available and
may be integrated into this scheme. Frequently abused
drugs such as bromoureides have to be determined by
other methods.
Tab. 13. Costs of a thin-layer Chromatographie screening (Drug-Skreen) and of an Emit test (Drug Abuse Urine Assay).
Costs Thin-layer chromatography
na = l n = 30 n = 50
Emit assay
n = l n = 30 = 50
Technician timeb
Reagents and pertinent supplies
Standaix^
Total
DM
DM
DM
DM
28.50
8.76
0.04
(33.30)
37.30
(70.56)
3.80
2.59
0.01
(4.44)
6.40
(10.83)
2.52
2.54 ·
<0.01
(4.00)
5.06
(9.06)
9.90
21.56
6.00
37.46
1.00
3.09
0.20
4.29
0.81
2.83
0.12
3.76
) n = number of specimens per series. *) costs per minute technician time: 0.30 DM. °) prices in parenthesis refer to the use of
toxicological control urine (Lederte diagnostics).
J. Clin. Chem. Clin. Bioehem. / Vol. 15,1977 / No. 5
282 Oellerich, Kiilpmann and Haeckel: Drug screening by enzyme immunoassay and thin-layer chromatography
.X^Drug^X.
<abuse suspected?>
Abuse of
bromoureides
suspected ?
opiates, barbiturates
oramphetami opiate or barbituratesuspected ?
Determination of bromoureides
by TLC and of bromine
by the method.of K/ssef
More specific methods such as GLC
Fig. 2. Flow scheme for the detection of drugs in urine.
TLC = Thin layer chromatography. GLC = Gas liquid chromatography.
By the use of the procedure described above the quality
of drug screening is considerably improved. The number
of false positive results is reduced. In the detection of
barbiturates false positive results decreased from 29%
to 5 %. The presence of amphetamine could be excluded
by Emit, when false positive results due to the inter^
ference of 4-aminophenazone occurred. Wrong results
for methadone, morphine and codeine could be elimi-
nated. Because of the greater sensitivity of Emit less
false negative results were obtained in cases of suspected
morphine and methadone abuse.
Furthermore time and costs are saved because the only
results confirmed by gas liquid chromatography, are
those which are divergent by thin layer ehrqmatography
and Emit. This seems to be important, if a rapid screening
of a large number of specimens is required. In this case
the confirmation of every positive result by gas liquid
chromatography would lead to an enormous workload
and to a delay of the results.
The described screening procedure appears to be sui-
table for routine urine testing arid toxicological
emergencies such as barbiturate poisoning. In accord-
ance with the results of Mule (19) andMdntyre (30)
the Emit system can be regarded as a valuable contribu-
tion to existing screening methods for the detection
of drugs of abuse.
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